Development and validation of two chromatographic methods for the simultaneous determination of raubasine and almitrine besmesylate in pharmaceutical dosage form  by Basha, Mai A. et al.
Bulletin of Faculty of Pharmacy, Cairo University (2013) 51, 89–94Cairo University
Bulletin of Faculty of Pharmacy, Cairo University
www.elsevier.com/locate/bfopcu
www.sciencedirect.comORIGINAL ARTICLEDevelopment and validation of two chromatographic
methods for the simultaneous determination of raubasine
and almitrine besmesylate in pharmaceutical dosage formMai A. Basha a,*, Kareem M. Younes c, Hanaa K. Mickael a, Faten A. El Aziz b,
Maissa Y. Salem ca National Organization of Drug Control and Research (NODCAR), Cairo, Egypt
b Egyptian National Regulatory Authority (ENRA), Cairo, Egypt
c Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, EgyptReceived 6 November 2012; accepted 11 February 2013











er review under responsibi
niversity.
Production an






cu.2013.Abstract A binary mixture of almitrine besmesylate (A) and raubasine (R) was determined by two
different chromatographic methods. The ﬁrst method was based on HPTLC separation of the two
drugs followed by densitometric measurement of their spots at 245 and 285 nm for A and R, respec-
tively. The separation was carried out using HPTLC silica gel F254 nanoplates with metha-
nol:ammonia (10:8, v/v) as developing solvent. The linearity was achieved over concentration
range of 0.5–8 lg/spot and 0.5–10 lg/spot with mean accuracy 100.79 ± 1.58 and 100.68 ± 1.78,
for A and R, respectively. The second method involved the determination of A and R using reversed
phase high performance liquid chromatography (HPLC) on C18 column using acetonitrile:potas-
sium dihydrogen orthophosphate buffer pH= 4.7 (70:30, v/v) as mobile phase with ﬂow rate at
2 ml/min. Quantitation was achieved using UV detection at 220 nm. A linear relationship was
obtained over a concentration range of 0.75–105 lg ml1 for both drugs with mean accuracy
100.85 ± 1.74 and 98.82 ± 1.31, for A and R, respectively. The methods were successfully applied
for the determination of the cited drugs in dosage forms. The proposed methods were validated
according to USP and were found to be valid and suitable for the assay of the cited drugs in dosage
forms in quality control laboratories.
ª 2013 Faculty of Pharmacy, Cairo University. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.224318103.
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Raubasine is an alkaloid used as a vasodilator; chemically, it is
related to reserpine.
Almitrine has been used as a respiratory stimulant in acute
respiratory failure. It is also used in combination with rauba-
sine for mental function impairment for the elderly.hosting by Elsevier B.V.Open access under CC BY-NC-ND license.
90 M.A. Basha et al.Fixed dose combinations containing A and R are widely
available in market for the medication and management of
peripheral vascular disorder.1
They have the following structures as shown in (Fig. 1).2
They are determined individually or simultaneously using
different analytical methods. The determination of R was done
by spectrophotometry,3 electrochemical methods,4 gas chro-
matography5 and HPLC.6–8
The determination of A was done by gas chromatography9
and HPLC methods.8,10 The binary mixture was determined
simultaneously by spectrophotometry11–13 and by HPLC.8,14
The aim of this work is to develop simple, accurate, rapid,
precise and validated chromatographic methods suitable for
routine analysis of this combination in dosage forms and qual-
ity control laboratories.2. Experimental
2.1. Apparatus
1 Shimadzu TLC scanning densitometer CS 9301pc
(Japan).
2 Precoated glass silica gel HPTLC nanoplates 10X10
GF254 (M N) (Germany).
3 Chromtech graduated glass micro syringe 25 ll
(Taiwan).
4 Glass jar with lid (5X15X5).
5 HPLC chromatography; Agilent 1200 series equipped
with Agilent quaternary pump G1311A, UV detector
VWD G1314B and manual injector (20 ll loop)
G1328B (Japan).
6 HPLC Column Thermo Hypersil BDS, C18 (250 ·
4.6 mm) 5 lm.
2.2. Materials
 Pure samples: Raubasine and Almitrine besmesylate pow-
ders were kindly supplied by Servier Pharmaceutical Com-
pany, October City, Egypt. The purity was found to be
101.529 ± 1.65 and 97.77 ± 1.22 for A and R, respectively
according to manufacturer procedure.Figure 1 Chemical structures of A and R. Market samples: Duxil tablets (Servier, Egypt pharmaceuti-
cal company) with Batch number 11173 were purchased
from the Egyptian market. Each tablet is claimed to contain
10 mg of raubasine and 30 mg of almitrine besmesylate.
 Triple distilled water – methanol for HPLC (SDFCL, India) –
acetonitrile for HPLC (SDFCL, India) – methanol (AR)
(SDFCL, India) – ammonia 33% (El NASR-EGYPT) –
potassium dihydrogen orthophosphate (AR grade) (ADWIC,
Egypt).
 Developing solvent for HPTLC method: methanol:ammo-
nia (33%) (10:8, v/v).
 Mobile phase for HPLC: acetonitrile:potassium dihydrogen
orthophosphate buffer (3.4 gm of KH2PO4 dissolved in
500 ml water) (70:30, v/v).
2.3. Preparations of standard solutions
2.3.1. Stock standard solutions
For HPTLC method. Solutions with a ﬁnal concentration of
2 mgml1 in methanol were prepared for A and R.
For HPLC method. Two solutions were prepared for each of A
and R with ﬁnal concentrations 150 lgml1 and 15 lgml1 in
methanol.
2.4. Laboratory prepared mixtures
HPTLC method
Into a series of 10- ml volumetric ﬂask, different aliquots of
stock standard solutions (2 mg ml1) were quantitatively
transferred and the volume was completed to obtain ﬁnal con-
centrations of 0.2, 0.6, 0.6, 0.2, 0.2 mg ml1 and 0.6, 0.4, 0.2,
0.8, 0.2 mg ml1 for A and R, respectively.
HPLC method
Into a series of 10- ml volumetric ﬂasks, different aliquots of
stock standard solutions were quantitatively transferred and
the volume was completed to obtain ﬁnal concentrations of 4,
6, 2, 9 lg m l1 and 4, 4, 6, 3 lg m l1 for A and R, respectively.
2.5. Pharmaceutical dosage form
10 tablets were accurately weighed and powdered. A quantity
of powdered tablets equivalent to 10 mg R and 30 mg A was
weighed into a 250- ml beaker and 50- ml methanol was added.
The suspension was sonicated for 15 min then ﬁltered into a
100- ml volumetric ﬂask. The residue was washed three times
each with 10- ml methanol and the washings were collected
on the same 100- ml volumetric ﬂask (solution A).
3- ml of solution A was quantitatively transferred into a
100- ml volumetric ﬂask and the volume was completed with
methanol (solution B).
3. Procedures
3.1. Construction of calibration curves
3.1.1. Working standard solutions
HPTLC method. Into 2 separate sets of 10- ml volumetric
ﬂasks, different aliquots of stock standard solutions
Figure 2 TLC chromatogram of mixture of (1) R 2 mg/ml and
(2) A 1 mg/ml at 280 nm.
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completed with methanol to obtain ﬁnal concentrations ranges
of 0.1–1.8 mg m l1 and 0.1–2 mg ml1 for A and R,
respectively.
5 ll from each of the working standard solutions was ap-
plied separately onto the HPTLC plate in triplicate. The spots
were spaced 1 cm apart from each other and 1 cm from the
bottom edge of the plate. The plate was developed ascendingly
to a distance of 8 cm. using methanol:ammonia (10:8, v/v) as
developing solvent in glass chamber previously saturated with
developing solvent for 10 min at room temperature. The plate
was removed, dried in air then scanned at 285 nm and 245 nm
for R and A, respectively. The peak area was recorded. The
calibration curve was plotted between peak area and concen-
tration and the regression equation was computed.
HPLC method. Into two separate sets of 10- ml volumetric
ﬂasks, different aliquots of stock standard solutions of
150 lg ml1 or 15 lg ml1 were quantitatively transferred.Figure 3 HPLC chromatogram of 20 ll injection oThe volume was completed with methanol to obtain a ﬁnal
concentration range of 0.75–105 lg ml1 for both A and R.
20 ll from each of the working standard solutions was in-
jected separately into the HPLC chromatograph, the ﬂow rate
was kept at 2 ml/min at ambient temp and eluent was moni-
tored at 220 nm .The separation was performed on C18 column
using acetonitrile:potassium dihydrogen orthophosphate buf-
fer pH = 4.7 (70:30, v/v) as mobile phase. The peak area
was recorded. The calibration curve was plotted between peak
area and concentration and the regression equation was
computed.
3.2. Laboratory prepared mixtures
HPTLC method: 5 ll of laboratory prepared mixture was ap-
plied onto TLC plate, the procedure described under construc-
tion of calibration curve was repeated and the concentration of
each drug was computed from the regression equation.
HPLC method: 20 ll of laboratory prepared mixtures was
injected separately into the HPLC chromatograph, the proce-
dure described under construction of calibration curve was re-
peated and the concentration of each drug was computed from
the regression equation.
3.3. Analysis of pharmaceutical dosage form
Proceed as detailed under Section 2.5 using 5 ll of test solution
A for the HPTLC method and 20 ll of test solution B for
HPLC method.
4. Results and discussion
By reviewing the literature in hand, it was found that no TLC
methods were published for the simultaneous determination of
binary mixture of A and R while few HPLC methods were
reported8,14
Therefore the aim of this work was to develop and validate
chromatographic methods for simultaneous determination of
the cited drugs.f mixture of (1) R 10 lg/ml and (2) A 30 lg/ml.
Table 1 System suitability parameters for the proposed methods.
Parameter HPTLC HPLC
A R A R
Retention time, min (Rt) or (Rf) 0.2 0.8 6.293 1.758
Tailing factor (T) 1 1 1 0.937
Theoretical plates (N) – – 2438.48 428.043
Capacity factor 4 0.25 2.52 4.79
Resolution 5.8 10.065
Height equivalent to theoretical plate (HETP) – – 0.01 0.058
Table 2 Assay validation scheme and regression equation parameters for the proposed HPLC and HPTLC methods.
Parameter HPTLC HPLC
A R A R
Concentration range 0.5–8 lg/spot 0.5–10 lg/spot 0.75–105 lg/ml 0.75–105 lg/ml
Regression equation
-Slope 578.57 713.96 64.898 125.27
-SE of slope 25.92 7.53 0.883 0.54
-Intercept 694.01 640.48 -11.303 -82.423
-SE of intercept 5.548 27.27 15.07 25.86
-Correlation coeﬃcient (r) 0.9998 0.9995 0.9998 0.999
Accuracy (Mean ± SD) 100.79 ± 1.58 100.68 ± 1.78 100.85 ± 1.74 98.82 ± 1.31
Precision
-Intraday precision* 100.29 ± 1.82 99.24 ± 0.84 98.77 ± 1.87 98.21 ± 0.88
-Intermediate precision** 101.14 ± 0.42 99.61 ± 1.004 102.32 ± 0.38 101.62 ± 1.16
Robustness*** 102.61 ± 0.21 99.49 ± 0.31 99.63 ± 0.15 98.57 ± 0.29
LOD# lg/ml or lg/ spot 0.0298 0.01636 0.153 0.0819
LOQ# lg/ml or lg/ spot 0.0995 0.0545 0.513 0.273
* For concentrations 3, 4, 5 lg/spot of A and 2.5,3,4 of R for HPTLC and 0.75,45,75 lg/ml of A and 15, 45, 75 lg/ml of R for HPLC.
** For concentrations 3, 4 lg/spot of A and R for HPTLC and 45, 75 lg/ml of A and 15, 45 lg/ml of R for HPLC and.
*** By changing pH± 0.1, changing mobile phase composition, changing saturation time ±5 min and changing the scaling wavelength
±1 nm.
# Calculated according to the following equations LOD= 3SD/a and LOQ= 10SD/a, a= slop.











A R A R
1 3 1:3 99.49 100.73 4 4 1:1 102.74 99.02
3 2 3:2 101.66 101.8 6 4 3:2 99.50 101.37
3 1 3:1 102.9 99.64 2 6 1:3 101.72 98.89
1 4 1:4 98.25 101.28 9 3 3:1 99.80 102.74
1 1 1:1 100.00 99.00
Mean ± SD 100.46 ± 1.83 100.49 ± 1.15 100.49 ± 1.16 100.94 ± 1.55 100.50 ± 1.87
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developing solvents were tried as methanol:13.5 M ammonia
(10:2, v/v), methanol:ammonia (33%) (10:10, v/v), metha-
nol:ammonia (33%) (10:7, v/v). But the best resolution was
achieved using developing solvent consisting of metha-
nol:ammonia (33%) (10:8, v/v). Well deﬁned spots were ob-
tained when the chamber was saturated with developing
solvent for 10 min at room temperature. The Rf values were
found to be 0.2 and 0.8 for A and R, respectively. Thewavelengths chosen were 245 nm and 285 nm for A and R,
respectively which are the maximum wavelengths for the stud-
ied drugs to increase the sensitivity of the method. When the
plate was scanned with a densitometer, sharp and symmetric
peaks of A and R were obtained (Fig. 2) which allow the deter-
mination of both drugs with good accuracy and precision.
HPLC method: a simple method was adopted for the simul-
taneous determination of A and R either in bulk powder or in
pharmaceutical dosage form. Different mobile phases were
Table 4 Application of the standard addition technique to the analysis of A and R in their dosage forms by proposed methods.
Dosage form Found *% Pure added (mg/ml) Found * (mg/ml) Recovery %
HPTLC HPLC HPTLC HPLC HPTLC HPLC HPTLC HPLC
A in Duxil 30.0 mg
of tablets (Batch no. 12353)
101.1 ± 0.72 101.25 ± 0.39 1.5 3.0 1.548 3.037 103.2 101.23
3.0 6.0 3.057 5.972 101.9 99.543
3.0 12.0 2.959 11.7516 98.66 97.93
Mean ± S.D 101.58 ± 1.79 99.56 ± 1.65
R in Duxil 10.0 mg
of tablets (Batch no. 12353)
100.68 ± 0.79 101.25 ± 0.59 0.5 1.00 0.506 1.026 101.2 102.6
1.00 2.00 0.9902 1.987 99.02 99.35
1.00 4.00 0.984 3.968 101.62 99.2
Mean ± S.D 100.615 ± 1.39 100.38 ± 1.919
* Average of three determinations.
Table 5 Statistical comparison between proposed methods and manufacturer’s method.
HPTLC HPLC Manufacturer’s method**
A R A R A R
Bulk powder
Mean accuracy 100.79 100.68 100.85 98.82 101.529 97.77
SD 1.58 1.78 1.74 1.31 1.65 1.22
Variance 2.496 3.168 3.027 1.716 2.74 1.48
n 6 6 6 6 6 6
F test 1.097 2.129 1.101 1.153
t test 0.487 2.165 0.4073 1.135
DF
Mean accuracy 101.1 100.68 99.56 100.38 101.55 100.99
SD 0.72 0.79 1.65 1.919 0.74 0.62
Variance 0.5184 0.62 2.72 3.68 0.55 0.39
n 6 6 6 6 6 6
F test (4.95)* 1.07 1.585 4.90 2.64
t test (2.228)* 1.454 1.062 1.334 0.664
* The ﬁgures in parenthesis are the corresponding tabulated values at P= 0.0516.
** UV Spectrophotometric method, Servier Egypt for bulk powder and HPLC method, Servier Egypt for dosage form, through personal
communication.
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nol:water (90:10, v/v), methanol:potassium dihydrogen ortho-
phosphate buffer (85:15, v/v), acetonitrile:buffer (80:20, v/v)
different pH values were also tried but the best resolution
was achieved using a mobile phase consisting of acetoni-
trile:potassium dihydrogen orthophosphate buffer pH = 4.7
(70:30, v/v) which gave good resolution and sensitivity of both
drugs (Fig. 3).
The system suitability parameters were calculated accord-
ing to the USP15 and the values obtained are shown in Table 1.
Compared to reported HPLC methods, the proposed meth-
od has the advantages of being more economical than the man-
ufacturer’s method because the latter used methane sulphonic
acid as solvent and heptane sulphonic acid in mobile phase
which are expensive. The proposed HPLC method is also more
sensitive and a more rapid method than the method of El-
Sayed.14 Furthermore, it was validated according to USP
guidelines whereas the method of Wang et al8 did not apply
any validation scheme
The proposed methods were subjected to USP validation
protocol15 and the results obtained are shown in Table 2.
The results in this table show that the method is reproducibleand precise as shown by the small values of the RSD of the
intraday and intermediate precision. The robustness of the
method was studied by applying small and deliberate changes
in the chromatographic conditions such as by changing pH
±0.1, changing mobile phase composition, changing satura-
tion time ±5 min and changing the scaling wavelength
±1 nm. Low value of %RSD shows that the method is robust
and that deliberate small changes in the studied factors do not
lead to signiﬁcant changes in Rt or Rf values, area or symmetry
of the peaks.
The proposed methods were successfully applied for the
determination of A and R and simultaneously analysed in
the prepared mixtures with mean percentage recoveries of
100.46 ± 1.83 and 100.49 ± 1.15 for A and R, respectively
by HPTLC and 100.94 ± 1.55 and 100.50 ± 1.87 for A and
R, respectively by the HPLC method as shown in Table 3.
The proposed methods were successfully applied for the
determination of A and R in D.F and the mean recovery ob-
tained was 101.1 ± 0.72 and 100.68 ± 0.79 for A and R,
respectively by HPTLC and 101.25 ± 0.39 and
101.25 ± 0.59 for A and R, respectively by HPLC as shown
in Table 4.
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application of the standard addition technique and the mean
recoveries of added standard were 101.58 ± 1.79 and
100.615 ± 1.39 for A and R, respectively by HPTLC and
99.56 ± 1.65 and 100.55 ± 1.95 for A and R, respectively by
HPLC as shown in Table 4.
Statistical comparison between the results of determination
of A and R in D.F and in pure powdered form by the proposed
methods and those of the manufacturer’s method was done
and no signiﬁcant difference was observed at 95% conﬁdence
level as shown in Table 5.
5. Summary and conclusion
From the previous discussion, it could be concluded that the
proposed methods are simple and do not require sophisticated
techniques or instruments. The proposed HPTLC method is
the ﬁrst reported TLC method for the determination of the
mixture. It has the advantage of allowing determination of sev-
eral samples at the same time.
Both methods are also sensitive, selective and can be used
for the routine analysis of raubasine, and almitrine besmesy-
late in their available dosage forms. The methods are also suit-
able and valid for application in quality control laboratories.
6. Conﬂict of interest
None.
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